Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifeward Ltd. on May 18, 2026. The report discloses an executive appointment effective May 1, 2026. Lifeward Ltd. is incorporated in Israel and trades on the Nasdaq Capital Market under the symbol LFWD.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The material change reported is the appointment of Keith D. Rose, M.D., as Chief Medical Officer. Dr. Rose has been with the company since March 2023, previously serving as Vice President, Medical Affairs, and Medical Director for Neurosciences. His prior experience includes roles at Biocodex, Inc. and Novocure, Inc.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on strategy, or discussion of risks and contingencies. The document is limited to the announcement of the executive appointment.
Key Facts for Investors
- Keith D. Rose, M.D., was appointed Chief Medical Officer effective May 1, 2026.
- Dr. Rose brings over three years of internal experience at Lifeward, specifically in neurosciences medical affairs.
- The appointment was signed by Almog Adar, Chief Financial Officer, on May 19, 2026.
- No financial data or operational metrics are included in this specific filing.